Variant:
rs4680 at chr22:19951271 in COMT (VIP)

Alleles (on + chromosomal strand)
G > T
G > C
G > A
Amino Acid Translation
Val108Met
Alternate Names:
COMP: Val158Met, COMT:Val108Met, c.322G>A, c.472G>A, g.18331271G>A, g.27009G>A, g.3103421G>A, p.Val108Met, p.Val158Met

Clinical Annotations

To see the clinical annotation for this variant please register or sign in.

Variant Annotations

PharmGKB variant annotations provide information about variant-drug pairs based on individual PubMed publications. Each annotation represents information from a single paper and the goal is to report the information that the author states, not an interpretation of the paper. The PMID for supporting PubMed publications is found in the "Evidence" field.

Information presented, including study size, allele frequencies and statistics is taken directly from the publication. However, if the author does not correct p-values in cases of multiple hypotheses, curators may apply a Bonferroni correction. Curators attempt to report study size based on the actual number of participants used for the calculation of the association statistics, so the number may vary slightly from what is reported in the abstract of the paper. OMB Race Category information is derived from the paper and mapped to standardized categories. Category definitions may be found by clicking on the "OMB Race Category" link.

There are 9 annotations for this variant. Register or sign in to see them.

There are 3 disease-related annotations for this variant. Register or sign in to see them.

VIP Variant in COMT

Because COMT exists in membrane-bound and soluble forms, the numbering for the position of the polymorphism described here is different for the two forms. For the soluble form, the polymorphism is located at position 108, while for the membrane-bound form with its extra 50 N-terminal amino acids, this identical polymorphism is located at position 158. The Met allele is the low activity allele and is often referred to in the literature as the "L" allele; the Val allele is the high activity allele and is often referred to in the literature as the "H" allele.

Schizophrenia
The relationship between COMT genotype and schizophrenia is apparently complex. Some studies have shown that the Met allele is associated with susceptibility to schizophrenia [Article:9535125] (Japanese), [Article:12372660]. One study on a white (Turkish) population showed a possible connection between the Met/Met (L/L) genotype and more severe clinical manifestations of schizophrenia [Article:11525417] (Turkish), and another study showed that the low activity Met allele is associated with poorer performance on tests of cognitive function and decreased prefrontal cortex physiological responses in patients with schizophrenia or schizoaffective disorder [Article:11381111] (North American, European ancestry). This same study showed that the L allele is more frequently transmitted to siblings with schizophrenia. However, a study involving ethnic Chinese patients in Taiwan failed to show any association between V158 polymorphism and schizophrenia, although heterozygotes did have a later age at onset than Met/Met (L/L) individuals [Article:11150892] (Ethnic Chinese from Taiwan). They also saw no association with violent behaviors in this group. Other studies have also failed to show an association between COMT genotype and schizophrenia [Article:12815736] (Japanese), [Article:14520117] (Caucasian-Finnish).

Schizophrenia and Drug Response
The Met (L) allele is associated with the requirement for a higher dose of neuroleptic and a tendency toward a higher rate of treatment-resistant schizophrenia [Article:12815736] (Japanese). Among a group of Finnish schizophrenics, non-responders to neuroleptics were more likely to possess a Met (L) allele, and additional risk of being a non-responder was seen if the patient possessed both a Met (L) allele as well as a low activity MAOA polymorphism, a particular NOTCH4 allele, or a high activity (D) ACE allele [Article:14520117] (Caucasian-Finnish), [Article:15115916] (Caucasian-Finnish), [Article:12729939] (Caucasian-Finnish)]. Other studies involving patients with schizophrenia or schizoaffective disorder who were treated with olanzapine or other antipsychotic drugs showed that the Met (L) allele is associated with improved working memory and prefrontal cortical physiology, as well as with an improvement in negative symptom ratings [Article:15522252, 15465976]. However, one study failed to show any association between COMT genotype and the response of schizophrenics to risperidone treatment [Article:14610521] (Japanese), while another was unable to confirm some of the results from the Finnish study mentioned above [Article:6702905].

Other Psychiatric and Neurological Disorders
The Met (L) allele is associated with panic disorder and homozygotes for this allele exhibit poorer treatment response [Article:12359690] (Korean). Anxiety-related personality traits associated with the Met (L) allele include increased anticipatory worry and fear of uncertainty [Article:12605099] and low extraversion and neuroticism [Article:15956988], though the latter association is seen only in women. The Met (L) allele was shown by one group to be associated with bipolar affective disorder [Article:9352569] (Han Chinese), while another study indicated that the Met (L) allele is associated with depressive disorder but not bipolar disorder [Article:9631418] (Japanese). Another enticing study showed a potential association between the Met (L) allele and obsessive-compulsive disorder, but only in women [Article:11840516]. An analysis of COMT genotype and Parkinson's disease in a Taiwanese population indicated that the Met (L) allele is associated with Parkinson's Disease in women and in individuals with an earlier age of diagnosis [Article:12465073] (mostly Caucasian of European descent). In addition, the Met (L) allele is associated with narcolepsy in women and with a lower daily dose of modafinil in these patients, while the Val (H) allele is associated with poorer response to this drug [Article:11990384].

Other Drug Responses
In one family-based haplotype analysis, the Val (H) allele was associated with heroin addiction [Article:11054766] (Israeli), while another study showed that individuals with a Val (H) allele may be more likely to be multiple substance abusers [Article:9259381] (North American). Women carrying two Met (L) alleles are more likely to be ex-smokers than women who carry a Val (H) allele [Article:15900212]. These studies seem to indicate that Val (H) alleles may predispose individuals toward drug addiction, while the presence of Met (L) alleles may make it easier for people to successfully combat an addiction. One study on mu-opioids showed that Met (L) homozygosity is associated with decreased responses to pain and a decreased pain stimulus to reach similar levels of pain intensity [Article:12595695]. A study of morphine dosage in cancer patients indicated that Val (H) homozygotes received more morphine than did Met (L) homozygotes [Article:15927391] (Caucasian-Norway).

Breast Cancer
The Met (L) allele has been suggested to be associated with an increased risk for breast cancer [Article:15455371] (Taiwanese), [Article:10519398] (Taiwanese). The suggested mechanism is that the Met (L) allele is associated with decreased expression of COMT protein resulting in a decrease in the formation of methylated, and thereby inactivated, catecholestrogens [Article:9407957, 10519398]. The details of a possible COMT breast cancer association are still vague and the results of association studies have been contradictory [Article:11401913] (Finnish), [Article:11434504] (Korean). The initial study reported an increased risk of breast cancer for the Met (L) allele only in post-menopausal women [Article:9407957], but a series of later studies reported an increased risk only in pre-menopausal women [Article:9605753, 14575568, 15388245, 15538046]. Studies have also shown that risk of breast cancer with a COMT Met (L) allele increases when high-risk alleles in other genes, such as UGT1A1, GSTT1, GSTM1, SOD2, CYP17A1, CYP1A1, and GSTP1 are also present [Article:9407957, 15455371] (Taiwanese), [Article:10519398] (Taiwanese). Finally, several studies indicated that there is little or no association between COMT genotype and breast cancer, at least in the populations studied [Article:9855007, 16191465]. For tables with information on the relationship between COMT and breast cancer, see [Article:10963624, 14637391].

Key Publications:
Drugs / Other Molecules
Diseases Anxiety Disorders 14 15 Bipolar Disorder 16 17 Breast Neoplasms 18 19 20 21 22 23 24 25 26 27 28 29 30 Depressive Disorder 31 Narcolepsy 32 Obsessive-Compulsive Disorder 33 Pain 34 Panic Disorder 35 Parkinson Disease 36 Schizophrenia 37 38 39 40 41 42 43 44 45 46 47 48 49 Substance-Related Disorders 50 51 52 53
Phenotype Datasets S-COMT functional protein variants

Appendix

Genomic Variant & GenBank ID: 3103421 G>A NT_011519
mRNA Variant & GenBank ID: 674 G>A on NM_000754
Protein Variant & GenBank ID: 158 Val>Met on NP_000745

Frequency Table

Population Reported Population OMB Drug Disease % Val (H) Allele % Met (L) Allele Number of Chromosomes Number of Samples % Val/Val (H/H) % Heterozygote % Met/Met (L/L) PMID Notes
Disease Population Frequencies
Caucasian (Norway) White morphine Neoplasms 44 56 414 207 21.2 46.4 32.4 [Article:15927391]
Japanese Asian neuroleptics Schizophrenia 66.5 33.5 200 100 41 51 8 [Article:12815736] frequencies did not differ significantly from control
Caucasian-Finnish White neuroleptics; total Schizophrenia 48.4 51.6 188 94 27.6 41.5 30.9 [Article:14520117] for total schizophrenic population, frequencies did not differ significantly from the control
Caucasian-Finnish White neuroleptics; responders Schizophrenia 55.8 44.2 86 43 27.9 55.8 16.3 [Article:14520117]
Caucasian-Finnish White neuroleptics; non-responders Schizophrenia 42.2 57.8 102 51 27.5 29.4 43.1 [Article:14520117]
Japanese Asian risperidone Schizophrenia 61 39 146 73 37 48 15 [Article:14610521]
Ethnic Chinese from Taiwan Asian Schizophrenia 76.8 23.2 396 198 59.6 34.3 6.1 [Article:11150892]
not reported Unknown olanzapine Schizophrenia 55 45 60 30 26.7 56.7 16.6 [Article:15465976]
not reported Unknown antipsychotics (olanzapine, perphenazine), ziprasidone, clozapine, risperidone, quetiapine, haloperidol, paroxetine, benztropine, valproic acid, trihexyphenidyl, lithium, sertraline) Schizophrenia, Schizoaffective Disorder 53 47 40 20 25 55 20 [Article:15522252]
North American, European ancestry Unknown Schizophrenia, Schizoaffective Disorder 60 40 350 175 35 49 16 [Article:11381111]
Korean Asian Panic Disorder 61.8 38.2 102 51 43.1 37.3 19.6 [Article:12359690]
Mixed (African American, Asian American, Hispanic American/Latino, Native American, Filipino American, European American, Other or missing) Unknown anxiety-related personality traits (extraversion, neuroticism) 59.5 40.5 994 497 37.2 44.5 18.3 [Article:15956988]
European American only Unknown anxiety-related personality traits (extraversion, neuroticism) 51.6 48.4 492 246 26.8 49.6 23.6 [Article:15956988] subgroup from this study
Hispanic only Unknown anxiety-related personality traits (extraversion, neuroticism) 63.1 36.9 198 99 43.4 39.4 17.2 [Article:15956988] subgroup from this study
Israeli White Heroin Dependence 56.6 43.4 76 38 28.9 55.3 15.8 [Article:11054766]
mostly Caucasian of European descent White Parkinson Disease 46 54 612 306 19.3 53.3 27.5 [Article:12465073]
Taiwanese Asian Breast Neoplasms 71.5 28.5 938 469 50.5 42 7.5 [Article:15455371]
Taiwanese Asian Breast Neoplasms 73.3 26.7 236 118 57.6 31.4 11.0 [Article:10519398]
General Population Frequencies
Japanese Asian 71 29 306 153 48 46 6 [Articles:10459407, 9121699] Frequencies taken from PMID 10459407 without verification against original report
Japanese
Asian
64
36
300 150
39
51
10
[Articles:10459407, 9535125] Frequencies taken from PMID 10459407 without verification against original report
Japanese Asian 65
35
270
135
43
44
13
[Articles:10459407, 9631418]
Frequencies taken from PMID 10459407 without verification against original report
Japanese
Asian
68.7 31.3
402 201 43.8 49.8
6.5
[Article:12815736]
control population for study
Chinese Asian
75
25
124 62
60
31
9
[Articles:10459407, 9159741] Frequencies taken from PMID 10459407 without verification against original report
Chinese Asian
73
27
198 99
53
40
7
[Articles:10459407, 9110105] Frequencies taken from PMID 10459407 without verification against original report
Han Chinese Asian
82
18
196 98
67
30
3
[Articles:10459407, 9352569]
Frequencies taken from PMID 10459407 without verification against original report
Ethnic Chinese from Taiwan Asian

73.1 26.9
376
188
52.1 42.0 5.9 [Article:11150892] control population for study
Taiwanese Asian
Breast Neoplasms 74.5 25.5 1480 740
56.8 35.4
7.8
[Article:15455371] control population for study
Taiwanese Asian
Breast Neoplasms 74.8 25.2 250 125
52.8
44.0
3.2
[Article:10519398] control population for study
Korean Asian
Panic Disorder
81.1
18.9
90
45
64.5
33.3
2.2
[Article:12359690] control population for study
Israeli White
Heroin Dependence 39.5 60.5
76 38 13.2
52.6
34.2
[Article:11054766] control population for study
North American Unknown
60
40
174 87
34
51
15
[Articles:10459407, 8886163]
Frequencies taken from PMID 10459407 without verification against original report
North American Unknown
44
56
248
124
18
51
31
[Articles:10459407, 9259381]
Frequencies taken from PMID 10459407 without verification against original report
North American Mixed European
Unknown
60
40
174 87
34
51
15
[Articles:10459407, 9034544]
Frequencies taken from PMID 10459407 without verification against original report
North American Mixed European Unknown
60
40
174 87
34
51
15
[Articles:10459407, 9264133]
Frequencies taken from PMID 10459407 without verification against original report
North American Mixed European
Unknown
58
42
296
148
33
49
18
[Articles:10459407, 9114031]
Frequencies taken from PMID 10459407 without verification against original report
North American Mixed European Unknown
51
49
258 129
24
54
22
[Articles:10459407, 9532347]
Frequencies taken from PMID 10459407 without verification against original report
North American, European ancestry Unknown
Schizophrenia, Schizoaffective Disorder
54
46
110
55
27
55
18
[Article:11381111] control population for study
Caucasian
White
48
52
346
173
23
51
26
[Articles:10459407, 8941353]
Frequencies taken from PMID 10459407 without verification against original report
mostly Caucasian of European descent White
Parkinson Disease 49 51 374 187
26.7
43.9
29.4
[Article:12465073] control population for study
European
Unknown
49
51
242 121
24
51
25
[Articles:10459407, 9270905]
Frequencies taken from PMID 10459407 without verification against original report
Finnish
White
42
58
152
76
18
46
36
[Articles:10459407, 9110364]
Frequencies taken from PMID 10459407 without verification against original report
Caucasian-Finnish
White
47.9 52.1 188 94 23.4 48.9 27.7 [Article:14520117] control population for study
United Kingdom Unknown
47
53
156 78
26
42
32
[Articles:10459407, 8561211]
Frequencies taken from PMID 10459407 without verification against original report
Spanish White
57
43
226 113
31
50
19
[Articles:10459407, 8988970] Frequencies taken from PMID 10459407 without verification against original report
Numbered footnotes are links to supporting evidence.

Connected Drugs

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
benztropine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
clomipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
fluvoxamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
haloperidol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
heroin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lithium
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
modafinil
No Dosing Guideline available No Drug Label available CA VA VIP No VIP available
morphine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
nicotine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
olanzapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
paroxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
quetiapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
risperidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
sertraline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
trihexyphenidyl
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
valproic acid

Connected Drug Classes

Evidence Drug Class
Variant Annotation, VIP Annotation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA VIP No VIP available
antipsychotics
VIP Annotation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Lithium

Connected Diseases

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Anxiety Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA VIP No VIP available
Bipolar Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Breast Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Depressive Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Narcolepsy
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA VIP No VIP available
Obsessive-Compulsive Disorder
No Dosing Guideline available No Drug Label available CA No Variant Annotation available VIP No VIP available
Pain
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Panic Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Parkinson Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA VIP No VIP available
Schizophrenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Substance-Related Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
tardive dyskinesia

Publications related to rs4680 at chr22:19951271: 42

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association study between genetic monoaminergic polymorphisms and OCD response to clomipramine treatment. Arquivos de neuro-psiquiatria. 2011. Miguita Karen, et al. [Article:21625751@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. European psychiatry : the journal of the Association of European Psychiatrists. 2010. Benedetti F, et al. [Article:20619611@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics. 2010. McCarthy Michael J, et al. [Article:21047205@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Molecular psychiatry. 2008. Bakker P R, et al. [Article:18180754@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenetics and genomics. 2008. Munafò Marcus R, et al. [Article:18192898@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007. Johnstone Elaine C, et al. [Article:17548664@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007. Reyes-Gibby Cielito C, et al. [Article:17156920@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics. Journal of clinical psychopharmacology. 2006. Nolan Karen A, et al. [Article:16702905@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. International journal of cancer. Journal international du cancer. 2005. Cheng Ting-Chih, et al. [Article:15455371@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
COMT polymorphisms and anxiety-related personality traits. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2005. Stein Murray B, et al. [Article:15956988@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic susceptibility of catechol-O-methyltransferase polymorphism in Japanese patients with breast cancer. Oncology reports. 2005. Inoue Hiroshi, et al. [Article:16077979@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005. Rakvåg Trude Teoline, et al. [Article:15927391@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenetics and genomics. 2005. Colilla Susan, et al. [Article:15900212@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biological psychiatry. 2004. Weickert Thomas W, et al. [Article:15522252@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics. 2004. Anttila Sami, et al. [Article:15115916@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. The American journal of psychiatry. 2004. Bertolino Alessandro, et al. [Article:15465976@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2003. Inada Toshiya, et al. [Article:12815736@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2003. Illi Ari, et al. [Article:12729939@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia. Journal of clinical psychopharmacology. 2003. Illi Ari, et al. [Article:14520117@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism. Psychiatric genetics. 2003. Enoch Mary-Anne, et al. [Article:12605099@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science (New York, N.Y.). 2003. Zubieta Jon-Kar, et al. [Article:12595695@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. The pharmacogenomics journal. 2003. Yamanouchi Y, et al. [Article:14610521@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Association between the COMT locus and obsessive-compulsive disorder in females but not males. American journal of medical genetics. 2002. Alsobrook John P, et al. [Article:11840516@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Archives of toxicology. 2002. Kocaba¿ Neslihan Aygün, et al. [Article:12415427@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biological psychiatry. 2002. Bilder Robert M, et al. [Article:12372660@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2002. Goudreau John L, et al. [Article:12465073@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Catechol O-methyltransferase genetic polymorphism in panic disorder. The American journal of psychiatry. 2002. Woo Jong-Min, et al. [Article:12359690@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil. The pharmacogenomics journal. 2002. Dauvilliers Y, et al. [Article:11990384@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphic catechol-O-methyltransferase gene and breast cancer risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2001. Mitrunen K, et al. [Article:11401913@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Limited association between a catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan. International journal of clinical oncology / Japan Society of Clinical Oncology. 2001. Hamajima N, et al. [Article:11706521@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Association analysis of a functional catechol-o-methyltransferase gene polymorphism in schizophrenic patients in Taiwan. Neuropsychobiology. 2001. Liou Y J, et al. [Article:11150892@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics. 2001. Yim D S, et al. [Article:11434504@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2001. Egan M F, et al. [Article:11381111@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association between symptomatology and prognosis. Psychiatric genetics. 2001. Herken H, et al. [Article:11525417@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. American journal of medical genetics. 2000. Horowitz R, et al. [Article:11054766@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer research. 1999. Huang C S, et al. [Article:10519398@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer research. 1998. Thompson P A, et al. [Article:9605753@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression. Neuroreport. 1998. Ohara K, et al. [Article:9631418@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Association study of a functional catechol-O-methyltransferase gene polymorphism in Japanese schizophrenics. Neuroscience letters. 1998. Ohmori O, et al. [Article:9535125@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. American journal of medical genetics. 1997. Vandenbergh D J, et al. [Article:9259381@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer research. 1997. Lavigne J A, et al. [Article:9407957@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder. Pharmacogenetics. 1997. Li T, et al. [Article:9352569@PubMed]

Cross-References

UCSC Golden Path:
chr22:19951271
dbSNP:
rs4680
ALFRED:
SI000155L
HapMap:
rs4680
JSNP:
ssj0007832

Platform Availability

  • Affymetrix
  • Illumina

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.